Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 137580
Corporate User License Price USD 6000
Corporate User License Price INR 412740
Site License Price USD 4000
Site License Price INR 275160
Request a Quote

Report Title

nasopharyngeal cancer-pipeline review, h2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

nasopharyngeal cancer-pipeline review, h2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

nasopharyngeal cancer-pipeline review, h2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

nasopharyngeal cancer-pipeline review, h2 2017



Executive Summary

Nasopharyngeal Cancer-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer-Pipeline Review, H2 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 13, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 2 and 5 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Nasopharyngeal Cancer-Overview 7

Nasopharyngeal Cancer-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Nasopharyngeal Cancer-Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Nasopharyngeal Cancer-Companies Involved in Therapeutics Development 27

Advenchen Laboratories LLC 27

Ambrx Inc 27

arGEN-X BV 28

Atara Biotherapeutics Inc 28

AVEO Pharmaceuticals Inc 29

BeiGene Ltd 29

BioDiem Ltd 30

Biomics Biotechnologies Co Ltd 30

Bristol-Myers Squibb Company 31

CBT Pharmaceuticals Inc 31

Celgene Corp 32

Cell Medica Ltd 32

F. Hoffmann-La Roche Ltd 33

GlaxoSmithKline Plc 33

Incyte Corp 34

Jiangsu Hengrui Medicine Co Ltd 35

MedImmune LLC 35

Merck & Co Inc 36

Merck KGaA 36

Millennium Pharmaceuticals Inc 37

Neonc Technologies Inc 37

Novartis AG 38

Ono Pharmaceutical Co Ltd 38

Otsuka Holdings Co Ltd 39

Systimmune Inc 39

Tessa Therapeutics Pte Ltd 40

Theravectys SA 40

Viracta Therapeutics Inc 41

Yabao Pharmaceutical Group Co Ltd 41

Nasopharyngeal Cancer-Drug Profiles 42

alisertib-Drug Profile 42

Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer-Drug Profile 48

apatinib-Drug Profile 49

APG-1387-Drug Profile 55

ARGX-110-Drug Profile 56

ATA-129-Drug Profile 61

atezolizumab-Drug Profile 64

avelumab-Drug Profile 84

azacitidine-Drug Profile 95

baltaleucel-T-Drug Profile 101

bevacizumab-Drug Profile 103

BGBA-317-Drug Profile 115

CBT-501-Drug Profile 118

Cellular Immunotherapy for EBV Associated Malignancies-Drug Profile 120

Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer-Drug Profile 121

Cellular Immunotherapy for Nasopharyngeal Cancer-Drug Profile 122

Cellular Immunotherapy for Oncology-Drug Profile 123

Cellular Immunotherapy for Oncology-Drug Profile 124

Cellular Immunotherapy for Oncology-Drug Profile 126

Cellular Immunotherapy for Oncology and Infectious Disease-Drug Profile 127

Cellular Immunotherapy to Target EPCAM for Oncology-Drug Profile 128

Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology-Drug Profile 129

Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer-Drug Profile 130

DC-120-Drug Profile 131

donafenib-Drug Profile 132

durvalumab + tremelimumab-Drug Profile 134

EBViNT-Drug Profile 140

Epstein-Barr virus vaccine-Drug Profile 141

ficlatuzumab-Drug Profile 142

GSK-2849330-Drug Profile 146

INCB-62079-Drug Profile 147

ipilimumab-Drug Profile 148

ipilimumab + nivolumab-Drug Profile 159

JS-001-Drug Profile 167

MAK-683-Drug Profile 169

Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma-Drug Profile 170

Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma-Drug Profile 171

MVA vaccine-Drug Profile 172

NEO-212-Drug Profile 173

nimotuzumab-Drug Profile 175

nivolumab-Drug Profile 180

OPB-111077-Drug Profile 229

PDR-001-Drug Profile 230

pembrolizumab-Drug Profile 233

SHR-1210-Drug Profile 294

SIM-005A-Drug Profile 296

Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer-Drug Profile 297

SV-638-Drug Profile 298

TT-10-Drug Profile 299

Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma-Drug Profile 301

Vaccine for Oncology-Drug Profile 302

Vaccine to Target EBV for Nasopharyngeal Carcinoma-Drug Profile 303

Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma-Drug Profile 304

VRx-3996-Drug Profile 305

Nasopharyngeal Cancer-Dormant Projects 307

Nasopharyngeal Cancer-Discontinued Products 308

Nasopharyngeal Cancer-Product Development Milestones 309

Featured News & Press Releases 309

Appendix 314

Methodology 314

Coverage 314

Secondary Research 314

Primary Research 314

Expert Panel Validation 314

Contact Us 314

Disclaimer 315

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Nasopharyngeal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2017

Nasopharyngeal Cancer-Pipeline by Ambrx Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by arGEN-X BV, H2 2017

Nasopharyngeal Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by BeiGene Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by BioDiem Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by Biomics Biotechnologies Co Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2017

Nasopharyngeal Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Celgene Corp, H2 2017

Nasopharyngeal Cancer-Pipeline by Cell Medica Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by GlaxoSmithKline Plc, H2 2017

Nasopharyngeal Cancer-Pipeline by Incyte Corp, H2 2017

Nasopharyngeal Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by MedImmune LLC, H2 2017

Nasopharyngeal Cancer-Pipeline by Merck & Co Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Merck KGaA, H2 2017

Nasopharyngeal Cancer-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Neonc Technologies Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Novartis AG, H2 2017

Nasopharyngeal Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by Otsuka Holdings Co Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by Systimmune Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Tessa Therapeutics Pte Ltd, H2 2017

Nasopharyngeal Cancer-Pipeline by Theravectys SA, H2 2017

Nasopharyngeal Cancer-Pipeline by Viracta Therapeutics Inc, H2 2017

Nasopharyngeal Cancer-Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017

Nasopharyngeal Cancer-Dormant Projects, H2 2017

Nasopharyngeal Cancer-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Advenchen Laboratories LLC

Ambrx Inc

arGEN-X BV

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

BeiGene Ltd

BioDiem Ltd

Biomics Biotechnologies Co Ltd

Bristol-Myers Squibb Company

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Neonc Technologies Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Systimmune Inc

Tessa Therapeutics Pte Ltd

Theravectys SA

Viracta Therapeutics Inc

Yabao Pharmaceutical Group Co Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person